A cochlear implant can deliver sound information to the inner ear, but its benefit also depends on the auditory nerve carrying that information to the brain. A new review in Hearing Research examines whether cell therapy might one day strengthen that connection for selected patients—and how researchers could identify the people most likely to benefit.
The paper, “Boosting auditory nerve function with cell therapy—status, surgical approach and potential candidates,” was written by researchers affiliated with Rigshospitalet, the University of Copenhagen, Eriksholm Research Centre, the University of Cambridge, and the Interacoustics Research Unit. It focuses on otic neural progenitor cells, which could potentially develop into cells that support or replace damaged auditory neurons.
The authors stress that this remains an investigational approach. The review proposes a framework for future research; it does not report that auditory nerve cell therapy has improved hearing in patients.
Why Poor Cochlear Implant Performance Is Not Enough to Identify Candidates
Some cochlear implant recipients continue to struggle with speech understanding despite technically successful surgery. It is tempting to attribute a disappointing result to a damaged auditory nerve, but the authors caution that poor performance has many possible causes.
Electrode position, device function, programming, limited audibility, rehabilitation, cognition, language, and central auditory processing can all affect outcomes.

The relevant nerve cells are spiral ganglion neurons, which transmit signals from the cochlea toward the brain. Although their function is essential to cochlear implant benefit, the review notes that studies counting these neurons after death have not found a consistent relationship between the number of surviving cells and a person’s speech recognition during life. The quality of the neural response, the electrode-to-neuron interface, and other patient factors may matter as much as—or more than—cell count alone.
For that reason, the authors argue that a low speech score should be the beginning of an investigation, not proof that someone needs neuronal replacement.
A Staged Approach to Patient Selection
The proposed pathway begins with repeated, standardized speech testing after adequate implant experience, optimized programming, and rehabilitation. Clinicians would then review implant integrity, aided audibility, electrode placement, and other technical or anatomical explanations.
Cognitive, linguistic, psychosocial, and central auditory factors would also need consideration.
Only after that workup would a research team weigh evidence for peripheral auditory nerve dysfunction. That assessment could combine the cause and duration of hearing loss with imaging, genetic findings, and physiological measurements. Finally, investigators would consider whether the expected benefit justified the surgical and treatment risks, with outcomes defined before enrollment.

The review discusses several potentially relevant groups, including people with postsynaptic auditory neuropathy, some patients with hearing loss following meningitis or ototoxic treatment, and cochlear implant users whose poor performance remains unexplained after a thorough evaluation.
These diagnoses do not, by themselves, establish that cell therapy would help. Even within a diagnostic group, the site and extent of damage can differ considerably.
The Measurement Challenge
For audiologists and implant teams, a central obstacle is the lack of a validated test that can specifically identify spiral ganglion degeneration in an individual patient. Electrically evoked compound action potentials, or eCAPs, can measure a response to implant stimulation, but the results are also affected by electrode position and the way electrical current spreads through the cochlea.
The authors assess newer approaches, including changes in eCAP responses with the interphase gap of a stimulation pulse and panoramic eCAP methods designed to estimate patterns of neural responsiveness along an electrode array. They also discuss electrically evoked auditory brainstem responses and intraoperative electrocochleography. Each may contribute useful information, especially when following changes within the same patient, but none currently provides a stand-alone eligibility test for auditory neuron cell therapy.
That distinction matters for clinical trials. If a study enrolls people whose main limitation is unrelated to the auditory nerve, a potentially useful therapy could appear ineffective.
Conversely, an apparent improvement in speech perception must be interpreted alongside changes in programming, rehabilitation, and ordinary variation in cochlear implant performance.
Delivery Is Feasible to Study, but Integration Remains Unproven
The review describes studies in donated human temporal bones that have tested surgical routes toward the modiolus, the central structure of the cochlea where spiral ganglion cell bodies reside. These studies support the technical feasibility of reaching the intended area, including approaches that may be compatible with an existing implant electrode.
Reaching the site is only one step. Transplanted cells would also need to survive, develop appropriately, connect with the auditory pathway, respond usefully to electrical stimulation, and remain safe over time. Future trials must examine risks such as inflammation, fibrosis, infection, vestibular effects, and changes in implant function.
The authors see two plausible early research settings: treatment for carefully selected existing implant users with persistent poor performance, or cell delivery during implantation for new recipients judged to be at high risk of nerve-related limitations. A stand-alone procedure for someone who retains useful acoustic hearing would require a particularly strong safety case because surgery could jeopardize that hearing.
From Research Collaboration to Clinical Questions
The paper is connected to a broader effort to develop auditory neuron cell therapy. In 2025, Lineage Cell Therapeutics and William Demant Invest began a collaboration involving Lineage’s experimental ReSonance (ANP1) program and researchers at Eriksholm. The review’s disclosure states that William Demant Invest and the William Demant Foundation funded the work, and that several authors have affiliations with Demant organizations.
The paper also discusses a separate planned early-stage trial of Rinri Therapeutics’ Rincell-1 therapy; that is a different cell therapy program.
For hearing care professionals, the immediate contribution of the review is a clearer definition of the problem future trials must solve.
Before auditory neuron replacement can become a clinical option, researchers need to identify patients whose nerve dysfunction is a dominant, treatable cause of limited benefit—and demonstrate that delivered cells improve meaningful outcomes safely and durably.
Reference:
- West N, Navntoft CA, Haywood N, et al. Boosting auditory nerve function with cell therapy—status, surgical approach and potential candidates. Hearing Research. 2026;481:109806.







